Halozyme Therapeutics Inc

Healthcare · Biotechnology

113.90$ -1.1% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 481 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement HALO
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	32	39	30	34	64	190	31	35	26	60	57	39	46	54	25	55	65	122	89	136	116	102	117	152	209	181	162	221	216	230	196	231	290	298	265	326	354	452	377	481	1,664
Cost of Revenue	9.1	8.0	7.5	7.8	8.3	7.5	3.1	0.8	0.6	5.6	4.6	1.9	22	17	5.8	5.7	5.6	26	18	23	19	22	16	34	47	42	35	50	55	52	46	57	49	42	66	64	73	102	109	79	363
Gross Profit	23	31	22	26	55	182	28	34	25	55	52	37	24	37	20	49	60	95	71	113	97	80	101	118	162	139	127	171	161	178	150	174	241	256	199	262	281	350	268	402	1,301
Research & Development	34	41	37	38	34	41	38	40	36	37	31	34	30	45	10	9.0	7.7	7.4	9.0	8.1	8.5	10	12	15	17	23	18	20	17	21	19	21	18	20	15	18	17	32	26	28	102
Selling, General & Administrative	12	12	13	13	13	15	14	14	15	18	18	17	18	24	13	11	12	13	11	12	13	14	14	57	34	38	37	39	35	38	35	36	41	42	42	42	46	77	58	57	238
Total Operating Expenses	45	54	50	51	47	56	52	54	50	55	49	51	48	69	23	20	19	18	20	20	22	24	26	84	78	65	73	77	73	77	54	57	77	80	57	59	63	95	83	114	356
Operating Income	-23	-23	-28	-25	8.1	126	-24	-20	-25	-0.1	3.0	-14	-25	-32	-3.2	30	40	78	51	93	76	57	76	34	83	75	54	94	88	101	96	117	163	176	142	202	218	254	185	288	944
Interest Expense	5.3	5.6	5.4	5.5	5.5	5.5	5.2	4.8	4.3	3.8	3.2	2.6	2.1	3.7	5.3	5.0	5.0	5.0	2.0	1.8	1.8	2.1	1.8	3.1	7.5	4.6	4.5	4.5	4.5	5.2	4.5	4.5	4.5	4.5	4.5	4.4	4.3	4.9	5.5	5.6	20
Pre-Tax Income	-28	-28	-33	-31	3.3	122	-27	-23	-28	-1.8	1.8	-15	-25	-34	-6.1	26	36	73	28	92	74	55	74	30	74	71	52	93	102	101	96	118	165	178	144	205	219	-101	180	285	583
Income Tax Expense	1.3	-0.4	0.2	0.2	0.6	-2.3	0.2	0.0	4.3	0.3	0.0	0.0	0.0	-0.1	0.0	0.1	0.1	0.1	0.2	0.1	-142	-12	14	7.3	12	13	13	18	20	16	19	24	28	41	26	40	44	41	30	55	170
Net Income	-29	-27	-33	-31	2.7	124	-27	-23	-28	-2.1	1.8	-15	-25	-34	-6.1	26	36	73	28	91	217	67	60	23	62	58	40	75	82	85	77	93	137	137	118	165	175	-142	150	230	414
EBITDA	-22	-22	-27	-24	8.6	126	-21	-17	-23	0.5	4.0	-11	-22	-30	0.1	32	42	79	31	94	77	58	77	46	110	82	77	118	129	127	121	143	190	203	169	230	244	-69	220	320	714

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings